Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
iBio announces partial adjournment of annual meeting to January 31 » 09:27
12/22/21
12/22
09:27
12/22/21
09:27
IBIO

iBio

/

+

iBio announced that it…

iBio announced that it has adjourned its 2021 Annual Meeting of Shareholders with respect to Proposals 4 and 5. The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 and Proposal 5 to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. iBio subsequently received additional votes "FOR" the proposals, as well as support from a number of shareholders who changed their "against" votes. Given that voting is still trending in favor of these proposals, the Company has adjourned the reconvened Annual Meeting to provide its shareholders additional time to vote. The Annual Meeting will resume with respect to Proposal 4 and 5 at 9:00 a.m. Eastern time on January 31, 2022.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

IBIO iBio
/

+

IBIO iBio
/

+

Hot Stocks
iBio announces partial adjournment of annual meeting to December 22 » 08:33
12/10/21
12/10
08:33
12/10/21
08:33
IBIO

iBio

/

+

iBio announced that its…

iBio announced that its annual meeting of stockholders scheduled for and convened yesterday has been partially adjourned to December 22, 2021 at 9:00 a.m. Eastern Time. A quorum was present at yesterday's Annual Meeting, and Proposals 1, 2 and 3 put forth in the definitive proxy statement received the requisite votes for approval. The Company's stockholders also approved Proposal 6 for the purpose of continuing to solicit votes in favor of Proposal 4 and Proposal 5. With over 60% of all shares voted, iBio stockholders are in favor of the reverse split and authorized share decrease by approximately a 2-to-1 margin. Results of votes cast "FOR" Proposals 4 and 5 to-date are 64% and 67%, respectively. Additionally, both of the leading proxy advisory firms have recommended that stockholders vote "FOR" the proposals. With a clear plurality of the vote in favor of the proposals and strong, independent third-party support for the reverse split and authorized share decrease, the Company is allowing additional time for stockholders holding approximately 40% of the shares that have yet to be voted the opportunity to express their views. Proposals 4 and 5 require a majority of all shares outstanding to vote "FOR" the measures, not just a plurality of the vote.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

IBIO iBio
/

+

IBIO iBio
/

+

Hot Stocks
iBio says ISS recommends shareholders vote for all proposals at meeting » 08:09
11/30/21
11/30
08:09
11/30/21
08:09
IBIO

iBio

/

+

iBio announced that…

iBio announced that Institutional Shareholder Services has joined Glass Lewis and Co., in recommending that the Company's stockholders vote "FOR" all proposals put forth in the definitive proxy statement prior to its Annual Meeting of Stockholders to be held on December 9, 2021. The voting recommendations of ISS and Glass Lewis are relied upon by institutional investment firms, mutual funds, and other fiduciaries globally for independent advice on shareholder voting and corporate governance. Neither firm has any business relationship with iBio, and iBio did not engage or compensate them for their analyses or recommendations.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Hot Stocks
iBio announces update for IBIO-202 program in light of Omicron variant » 08:56
11/29/21
11/29
08:56
11/29/21
08:56
IBIO

iBio

/

+

iBio announced an update…

iBio announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. On November 26, 2021, the World Health Organization's Technical Advisory Group on SARS-CoV-2 Virus Evolution classified Omicron as a Variant of Concern. According to the WHO, the Omicron variant has at least 30 mutations in the spike protein, which has been the target of first-generation COVID-19 vaccines. The Company believes that the N protein represents an important target for next-generation COVID-19 vaccines for several reasons. First, the N protein is abundantly expressed during infection and contains multiple immunogenic epitopes. Second, the N protein is more highly conserved than the S protein, and therefore, new variants may be less likely to escape vaccine protection. Third, research has shown that the N protein appears to be significantly more effective than the S protein in stimulating antibody-dependent natural killer cell activation, a critical element of the adaptive immune response that the SARS-CoV-2 virus attempts to evade

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Initiation
iBio initiated with an Outperform at JMP Securities » 06:25
11/29/21
11/29
06:25
11/29/21
06:25
IBIO

iBio

/

+

JMP Securities analyst…

JMP Securities analyst Roy Buchanan initiated coverage of iBio with an Outperform rating and $1.50 price target. The company's lead oncology therapeutic asset IBIO-101 is "novel in its approach and design" and could drive significant future value given its position in a "relatively uncrowded" target space, the analyst tells investors in a research note. The recent stock price decline is an "excellent opportunity" to invest in iBio's "unique" platform capabilities, Buchanan adds.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

11/29/21 JMP Securities
iBio initiated with an Outperform at JMP Securities
01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Initiation
iBio initiated with an Outperform at JMP Securities » 06:23
11/29/21
11/29
06:23
11/29/21
06:23
IBIO

iBio

/

+

JMP Securities analyst…

JMP Securities analyst Roy Buchanan initiated coverage of iBio with an Outperform rating and $1.50 price target.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Options
iBio options imply 26.1% move in share price post-earnings » 13:34
11/15/21
11/15
13:34
11/15/21
13:34
IBIO

iBio

/

+

Pre-earnings options…

Pre-earnings options volume in iBio is normal with calls leading puts 13:1. Implied volatility suggests the market is anticipating a move near 26.1%, or 19c, after results are released. Median move over the past eight quarters is 7.5%.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

Hot Stocks
iBio announces collaboration with UT Southwestern for IBIO-100 » 13:01
11/15/21
11/15
13:01
11/15/21
13:01
IBIO

iBio

/

+

iBio announced a research…

iBio announced a research collaboration with the University of Texas Southwestern Medical Center to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program. Among all the stromal cells that present in the tumor microenvironment, cancer-associated fibroblasts are one of the most abundant and critical components of tumor tissue, which provide physical support for tumor cells and can promote or retard tumorigenesis in a context-dependent manner. CAFs are also involved in the modulation of many components of the immune system, and recent studies have revealed their roles in immune evasion and poor responses to cancer immunotherapy. In addition, CAF response to chemotherapy is highly variable.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

Hot Stocks
iBio sees cash sufficient to fund operations through 1Q23  16:59
11/03/21
11/03
16:59
11/03/21
16:59
IBIO

iBio

/

+

 
ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Hot Stocks
iBio acquires FastPharming manufacturing facility » 16:58
11/03/21
11/03
16:58
11/03/21
16:58
IBIO

iBio

/

+

iBio, Inc. announced it…

iBio, Inc. announced it has purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital Limited. The company also acquired the approximate 30% equity interest in iBio CDMO, LLC. held by the Eastern Affiliates. As a result, the subsidiary and its intellectual property are now wholly-owned by iBio, it said in a statement. Before fees and settlement costs, the cost of the transaction was $28,750,000, comprised of $28,000,000 in cash plus warrants to purchase 1,000,000 shares of iBio common stock. iBio issued additional warrants to purchase 289,581 shares of common stock to pay for the final rent due. The total warrants to purchase 1,289,581 shares of common stock are immediately exercisable, will expire on October 10, 2026, and have an exercise price of $1.33 per share. iBio provided approximately $6,000,000 in capital to fund the purchase. To fund the remaining cash portion of the transaction, iBio entered into a $22,375,000 Senior Secured Term Loan with Woodforest National Bank.

ShowHide Related Items >><<
IBIO iBio
/

+

IBIO iBio
/

+

01/21/21 Cantor Fitzgerald
Cantor starts 'under the radar' iBio with Overweight, $3 target
01/21/21 Cantor Fitzgerald
iBio initiated with an Overweight at Cantor Fitzgerald
11/18/20 Alliance Global Partners
iBio price target lowered to $2 from $3.10 at Alliance Global Partners
IBIO iBio
/

+

  • 08
    Dec
IBIO iBio
/

+

IBIO iBio
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.